CURE’s gastrointestinal stromal tumor page features the latest cancer news and updates on gastrointestinal stromal tumors Through articles, videos, podcasts, and more, CURE brings readers the insights of experts, cancer survivors, patients, and advocates to ensure everyone is up to date in the gastrointestinal stromal tumor.
August 13th 2021
The location of gastrointestinal stromal tumors in the stomach predicts the mutation profile and drug sensitivity, which can provide direction for treatment decisions and selective genomic testing.
July 14th 2021
Gastrointestinal stromal tumors that are SDH deficient are less likely to respond to TKI treatment. A researcher discusses the exploration of a new drug that can work in this patient population.
July 13th 2021
Patients, clinicians and researchers should work together to find new therapies for rare cancers, one expert says.
July 1st 2021
Will patients be given a placebo? Are clinical trials safe? An expert answers these questions and more.
June 29th 2021
In patients with advanced gastrointestinal stromal tumors, a dose escalation of Qinlock after recommended treatment with the agent may be the best next step, answering for the lack of a next approved agent after Qinlock.
June 25th 2021
The combination of Gleevec and Xpovio demonstrated some promising results in a small group of patients with a rare form of advanced gastrointestinal cancer whose disease had failed to respond to prior first-line treatment with Gleevec.
June 22nd 2021
The findings open up the door for a fourth-line treatment option in patients with advanced gastrointestinal stromal tumors with disease progression.
June 9th 2021
Treatment with the study drug was associated with a doubling of a survival outcome in patients with advanced gastrointestinal stromal tumor, compared to placebo.
June 7th 2021
Twice-daily treatment with Qinlock following disease progression after treatment with fourth-line therapy in patients with advanced gastrointestinal stromal tumor was associated with extended survival outcomes.
April 16th 2021
Ayvakit demonstrated more durable survival outcomes in patients with unresectable/metastatic platelet-derived growth factor receptor A D842V-mutant gastrointestinal stromal tumors than tyrosine kinase inhibitors.
March 27th 2021
It is difficult for anyone to receive a cancer diagnosis, but when someone who is younger than average finds out they have gastrointestinal cancer, they may face other challenges.
March 24th 2021
In a recent interview with CURE®, an expert from Fox Chase Cancer Center discussed gastrointestinal stromal tumors (GIST) and addressed a multitude of topics including common symptoms associated with the disease, and potential future therapies that may be beneficial for patients.
March 23rd 2021
Results of a preliminary clinical trial show that MK-1775 — an investigational therapy — as a single agent, or in combination with Ayvakit, may be effective in the treatment of gastrointestinal stromal tumors. However, one of the study’s authors notes that further research is needed to determine a benefit in patients.
January 19th 2021
The data in the study presented at the ASCO Gastrointestinal Cancers Symposium demonstrated that while rare, stage 4 gastrointestinal stromal tumors often spread to the liver.
January 18th 2021
A group of patients with gastrointestinal cancers reported that a novel artificial intelligence-based search tool made it easier for them to find and understand cancer clinical trials. The tool, according to study authors, would not only help with trial accrual, but could also help improve trial diversity.
May 16th 2020
The targeted drug Qinlock, which interferes with the activity of proteins that drive gastrointestinal stromal tumor, has been approved by the Food and Drug Administration for patients with advanced disease that has progressed despite treatment with other kinase inhibitors.
January 13th 2020
Patients with gastrointestinal stromal tumors have a new targeted therapy that looks to tackle secondary mutations after it showed a strong response rate in the clinic.
January 10th 2020
The Food and Drug Administration approved Ayvakit for the treatment of adult patients with unresectable or metastatic gastrointestinal stromal tumor who exhibited a platelet-derived growth factor receptor alpha exon 18 mutation.
August 2nd 2017
How zeroing in on the mutation in gastrointestinal stromal tumors is adding years to patients’ lives
January 29th 2017
The Life Raft Group, a patient advocacy organization, is teaming up with research organizations to hopefully find the next wave of treatment for patients with gastrointestinal stromal tumors.
March 23rd 2016
Identified only a decade-and-a-half ago, GIST is already treatable with several targeted therapies, and scientists are researching more.
July 23rd 2015
The hospital agreed to release me back into the wild.
July 7th 2015
Is this a hospital or have I stepped on the "wayback machine" with the dial set to 1970?
June 24th 2015
The medical team had reached some conclusions.